Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer

Lung Cancer

Volumn 75, Issue 3, 2012, Pages 321-325

  Kim, Hee Joung ^a   Lee, Kye Young ^a   Kim, Young Chul ^b   Kim, Kyu Sik ^b   Lee, Sung Yong ^c   Jang, Tae Won ^d   Lee, Min Ki ^e   Shin, Kyeong Cheol ^f   Lee, Gwan Ho ^f   Lee, Jae Chol ^g   Lee, Jeong Eun ^h   Kim, Sun Young ^h  

^a Konkuk University School of Medicine   (South Korea)

^b Chonnam National University Medical School   (South Korea)

^c Korea University College of Medicine   (South Korea)

^d Kosin University   (South Korea)

^e Pusan National University School of Medicine   (South Korea)

^f Yeungnam University College of Medicine   (South Korea)

^g University of Ulsan College of Medicine   (South Korea)

^h Chungnam National University   (South Korea)

Author keywords

Direct gene sequencing; EGFR mutation; Non small cell lung cancer; Peptide nucleic acids (PNAs)

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GENOMIC DNA; PEPTIDE NUCLEIC ACID;

ADULT; AGED; ARTICLE; CANCER PATIENT; DIRECT GENE SEQUENCING; DNA EXTRACTION; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; MALE; MUTATION RATE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN CLAMPING; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PEPTIDE NUCLEIC ACIDS; PROTEIN KINASE INHIBITORS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA;

EID: 84856585835     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.08.005     Document Type: Article

References (22)

1. Ettinger D.S., Akerlew W., Bepler G., Blum M.G., Chang A., Cheney R.T., et al. Non-small cell lung cancer. J Natl Compr Canc Netw 2010, 8(7):740-801.
2. Jackman D.M., Miller V.A., Cioffredi L.A., Yeap B.Y., Jänne P.A., Riely G.J., et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009, 15(16):5267-5273.
3. Pao W., Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer, searching for the ideal method. Clin Cancer Res 2007, 13(17):4954-4955.
4. Sholl L.M., Xiao Y., Joshi V., Yeap B.Y., Cioffredi L.A., Jackman D.M., et al. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol 2010, 133(6):922-934.
5. Jänne P.A., Johnson B.E. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 2006, 12(Suppl. 14):4416s-4420s.
6. Kimura H., Kasahara K., Kawaishi M., Kunitoh H., Tamura T., Holloway B., et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small cell lung cancer. Clin Cancer Res 2006, 12(13):3915-3921.
7. Kimura H., Fujiwara Y., Sone T., Kunitoh H., Tamura T., Kasahara K., et al. High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci 2006, 97(7):642-648.
8. Molina-Vila M.A., Bertran-Alamillo J., Reguart N., Taron M., Castellà E., Llatjós M., et al. A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells. J Thorac Oncol 2008, 3(11):1224-1235.
9. Cohen V., Agulnik J.S., Ang C., Kasymjanova G., Batist G., Small D., et al. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer. Cancer 2010, 116(18):4309-4317.
10. Hwang T.S. Molecular biologic techniques in cytopathologic diagnosis. Korean J Pathol 2009, 43(5):387-392.
11. Kim S.K., Kim D.L., Han H.S., Kim W.S., Kim S.J., Moon W.J., et al. Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol 2008, 17(2):118-125.
12. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(10):947-957.
13. Inoue A., Kobayashi K., Usui K., Maemondo M., Okinaga S., Mikami I., et al. First-line gefitinib for patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009, 27(9):1394-1400.
14. Pirker R., Herth F.J., Kerr K.M., Filipits M., Taron M., Gandara D., et al. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol 2010, 5(10):1706-1713.
15. Choi J.J., Cho M.H., Oh M.A., Kim H.S., Kil M.S., Park H.K. PNA-mediated real-time PCR clamping for detection of EGFR mutations. Bull Korean Chem Soc 2010, 31(12):3525-3529.
16. Sakurada A., Kara-Guerra H., Liu N., Shepherd F.A., Tsao M.S. Tissue heterogeneity of EGFR mutation in lung adenocarcinoma. J Thorac Oncol 2008, 3(5):527-529.
17. Riely G.J., Politi K.A., Miller V.A., Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006, 12(24):7232-7241.
18. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7(3):169-181.
19. Mitsudomi T., Kosaka T., Endoh H., Horio Y., Hida T., Mori S., et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small cell lung cancer with postoperative recurrence. J Clin Oncol 2005, 23(11):2513-2520.
20. Jackman D.M., Yeap B.Y., Sequist L.V., Lindeman N., Holmes A.J., Joshi V.A., et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006, 12(13):3908-3914.
21. Riely G.J., Pao W., Pham D., Li A.R., Rizvi N., Venkatraman E.S., et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006, 12(3):839-844.
22. Maheswaran S., Sequist L.V., Nagrath S., Ulkus L., Brannigan B., Collura C.V., et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008, 359(4):366-377.